Table 5.
Summary of results for cognition and psychomotor endpoints
| Observed baseline mean (SD) | Observed week 4 mean (SD) | Model‐based LS mean change from baseline (95% CI)a | Difference in LS mean suvorexant versus placebo | ||||
|---|---|---|---|---|---|---|---|
| Measure | Suvorexant | Placebo | Suvorexant | Placebo | Suvorexant | Placebo | (95% CI), p valuea |
| MMSE, 0–30 scale | 23.4 (2.8) | 22.9 (3.0) | 24.3 (3.2) | 23.9 (3.2) | 0.9 (0.6, 1.3) | 0.9 (0.6, 1.3) | −0.0 (−0.5, 0.5), 0.952 |
| DS, attempts | 28.2 (12.1) | 26.4 (11.3) | 29.8 (11.3) | 28.7 (12.8) | 1.8 (0.5, 3.0) | 2.1 (0.9, 3.4) | −0.4 (−2.1, 1.4), 0.692 |
| DS, correct | 27.1 (12.1) | 25.4 (11.8) | 28.9 (11.4) | 27.6 (13.4) | 1.9 (0.6, 3.1) | 2.0 (0.8, 3.2) | −0.1 (−1.9, 1.6), 0.873 |
Abbreviations: CI, confidence interval; DS, Digit Symbol test; LS, least squares; MMSE, Mini‐Mental State Exam; SD, standard deviation.
a
Analyses are based on a longitudinal data analysis model with terms for baseline value, baseline severity category (MMSE score of 12 to 20, 21 to 26), age category (non‐elders, elders), sex, region, treatment, time point, and treatment‐by‐time point interaction as covariates. p values should be considered nominal.